Kovarik J M, Hoyer Peter F, Ettenger Robert, Punch Jeffrey, Soergel Marianne
Novartis Pharma AG, Building WSJ 27.4093, 4002 Basel, Switzerland.
Pediatr Nephrol. 2003 Dec;18(12):1275-9. doi: 10.1007/s00467-003-1260-8. Epub 2003 Oct 24.
Cyclosporine absorption profiling uses either the area under the concentration curve in the first 4 h post dose, AUC(0-4), or the concentration 2 h post dose (C2) to optimize immunosuppression in adult kidney and liver transplantation. We characterized C2 versus AUC(0-4) relationships over time after transplant and across transplant indications in 56 pediatric transplant patients. There were 36 kidney transplant patients aged 9.7+/-3.9 years. Nineteen of these patients were studied in the de novo period on day 7 post transplant and 17 in the maintenance phase more than 1 year post transplant. In addition, 20 liver transplant patients aged 8.9+/-4.2 years were studied in the maintenance phase. All patients had five blood samples collected over the 12-h dose interval that were analyzed by validated assay methods at a central laboratory. Pediatric C2 values were 1,463+/-658 ng/ml for de novo kidney, 954+/-322 ng/ml for maintenance kidney, and 619+/-339 ng/ml for maintenance liver transplant patients. C2 was a strong predictor of AUC(0-4) in all three pediatric groups, with coefficients of determination ( r(2)) ranging from 0.861 to 0.936. Although data were limited from the de novo period, the C2 versus AUC(0-4) regression was consistent over time after transplant and between transplant indications, with a regression slope of 2.50 in de novo kidney, 2.54 in maintenance kidney, and 2.76 in maintenance liver transplant recipients. These slopes were also comparable to that in adult maintenance kidney transplant patients (2.60). In conclusion, C2 versus AUC(0-4) relationships demonstrated consistency over time (de novo vs. maintenance phase), between transplant indications (kidney vs. liver), and across age groups (pediatric vs. adult patients). Average C2 values achieved with current pediatric cyclosporine dosing practices cluster around the target C2 ranges recommended for adults.
环孢素吸收曲线分析采用给药后首4小时的血药浓度-时间曲线下面积(AUC(0 - 4))或给药后2小时的血药浓度(C2)来优化成人肾移植和肝移植中的免疫抑制。我们对56例儿科移植患者移植后不同时间及不同移植指征下的C2与AUC(0 - 4)关系进行了特征分析。其中有36例肾移植患者,年龄为9.7±3.9岁。这些患者中,19例在移植后第7天的初始阶段接受研究,17例在移植后1年以上的维持阶段接受研究。此外,20例年龄为8.9±4.2岁的肝移植患者在维持阶段接受研究。所有患者在12小时给药间隔内采集5份血样,并在中心实验室采用经过验证的检测方法进行分析。儿科初始肾移植患者的C2值为1463±658 ng/ml,维持期肾移植患者为954±322 ng/ml,维持期肝移植患者为619±339 ng/ml。在所有三个儿科组中,C2都是AUC(0 - 4)的有力预测指标,决定系数(r(2))范围为0.861至0.936。虽然初始阶段的数据有限,但移植后不同时间及不同移植指征下C2与AUC(0 - 4)的回归是一致的,初始肾移植患者的回归斜率为2.50,维持期肾移植患者为2.54,维持期肝移植受者为2.76。这些斜率也与成人维持期肾移植患者的斜率(2.60)相当。总之,C2与AUC(0 - 4)的关系在不同时间(初始阶段与维持阶段)、不同移植指征(肾移植与肝移植)以及不同年龄组(儿科与成人患者)之间都表现出一致性。目前儿科环孢素给药方案所达到的平均C2值聚集在推荐给成人的目标C2范围内。